Symbols / EIKN Stock $8.16 -6.69% Eikon Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
EIKN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Roger M. Perlmutter M.D., Ph.D.
Exch · Country NMS · United States
Market Cap 441.50M
Enterprise Value 1.56B
Income -333.64M
Sales —
FCF (ttm) -208.89M
Book/sh -286.47
Cash/sh 6.21
Employees 384
Insider 10d —
IPO Feb 05, 2026
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.44
PEG —
P/S —
P/B -0.03
P/C —
EV/EBITDA -5.26
EV/Sales —
Quick Ratio 6.11
Current Ratio 6.34
Debt/Eq 91.11
LT Debt/Eq —
EPS (ttm) -6.18
EPS next Y -5.66
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-08
Earnings (prior) 2026-03-30
ROA -36.19%
ROE -125.02%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 54.14M
Shs Float 27.52M
Insider Own 15.50%
Instit Own 30.56%
Short Float 8.74%
Short Ratio 8.21
Short Interest 3.56M
52W High 17.40
vs 52W High -53.13%
52W Low 7.90
vs 52W Low 3.23%
Beta —
Impl. Vol. —
Rel Volume 0.28
Avg Volume 454.86K
Volume 128.84K
Target (mean) $25.60
Tgt Median $29.00
Tgt Low $7.00
Tgt High $34.00
# Analysts 5
Recom None
Prev Close $8.74
Price $8.15
Change -6.69%
About

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs using a platform that permits precise characterization of protein interactions in living cells. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$25.60
Mean price target
2. Current target
$8.16
Latest analyst target
3. DCF / Fair value
$-69.45
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.16
Low
$7.00
High
$34.00
Mean
$25.60

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-31 reit Wedbush Underperform → Underperform $7
2026-03-02 init Cantor Fitzgerald — → Overweight —
2026-03-02 init JP Morgan — → Overweight $29
2026-03-02 init B of A Securities — → Buy $34
2026-03-02 init Mizuho — → Outperform $26
2026-03-02 init Morgan Stanley — → Overweight $32
2026-02-26 init Wedbush — → Underperform $7
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-06 PERLMUTTER ROGER M Chief Executive Officer — 284,857 — —
2026-02-06 WOLFE JOSH Director and Beneficial Owner of more than 10% of a Class of Security — 5,695,010 — —
2026-02-06 COLUMN GROUP IV GP, LP Beneficial Owner of more than 10% of a Class of Security — 2,117,760 $14.50 $30,707,520
2026-02-06 COLUMN GROUP IV GP, LP Beneficial Owner of more than 10% of a Class of Security — 3,595,340 — —
2026-02-06 LUX VENTURE PARTNERS V, LLC Beneficial Owner of more than 10% of a Class of Security — 5,695,010 — —
2026-02-04 FRAZIER KENNETH C Director — 111,111 $18.00 $1,999,998
2026-02-04 FORESITE CAPITAL MANAGEMENT IV, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 55,555 $18.00 $999,990
2026-02-04 FORESITE CAPITAL MANAGEMENT IV, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 4,041,687 — —
2026-02-04 WOLFE JOSH Director and Beneficial Owner of more than 10% of a Class of Security — 277,776 $18.00 $4,999,968
2026-02-04 LUX VENTURE PARTNERS V, LLC Beneficial Owner of more than 10% of a Class of Security — 277,776 $18.00 $4,999,968
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Revenue
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
Operating Expense
338.94
+30.19%
260.34
-2.03%
265.74
Research And Development
250.32
+22.38%
204.54
-1.31%
207.26
Selling General And Administration
88.63
+58.81%
55.81
-4.56%
58.48
General And Administrative Expense
88.63
+58.81%
55.81
-4.56%
58.48
Other Gand A
88.63
+58.81%
55.81
-4.56%
58.48
Total Expenses
338.94
+30.19%
260.34
-2.03%
265.74
Operating Income
-338.94
-30.19%
-260.34
+2.03%
-265.74
Total Operating Income As Reported
-338.94
-30.19%
-260.34
+2.03%
-265.74
EBITDA
-299.24
-37.02%
-218.39
+2.60%
-224.21
Normalized EBITDA
-299.24
-37.02%
-218.39
+2.60%
-224.21
Reconciled Depreciation
24.18
-4.79%
25.39
+43.07%
17.75
EBIT
-323.41
-32.66%
-243.78
-0.75%
-241.96
Net Income
-324.25
-32.99%
-243.81
-0.75%
-242.00
Pretax Income
-324.25
-32.99%
-243.81
-0.75%
-242.00
Net Non Operating Interest Income Expense
14.73
-10.91%
16.53
-30.24%
23.70
Interest Expense Non Operating
0.84
+2600.00%
0.03
-20.51%
0.04
Net Interest Income
14.73
-10.91%
16.53
-30.24%
23.70
Interest Expense
0.84
+2600.00%
0.03
-20.51%
0.04
Interest Income Non Operating
15.57
-6.02%
16.56
-30.22%
23.74
Interest Income
15.57
-6.02%
16.56
-30.22%
23.74
Other Income Expense
-0.03
-966.67%
-0.00
-107.14%
0.04
Other Non Operating Income Expenses
-0.03
-966.67%
-0.00
-107.14%
0.04
Tax Rate For Calcs
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-324.25
-32.99%
-243.81
-0.75%
-242.00
Net Income From Continuing Operation Net Minority Interest
-324.25
-32.99%
-243.81
-0.75%
-242.00
Net Income From Continuing And Discontinued Operation
-324.25
-32.99%
-243.81
-0.75%
-242.00
Net Income Continuous Operations
-324.25
-32.99%
-243.81
-0.75%
-242.00
Normalized Income
-324.25
-32.99%
-243.81
-0.75%
-242.00
Net Income Common Stockholders
-333.64
-36.84%
-243.81
-0.75%
-242.00
Otherunder Preferred Stock Dividend
9.40
0.00
—
Diluted EPS
—
-7.45
-0.75%
-7.40
Basic EPS
—
-7.45
-0.75%
-7.40
Basic Average Shares
—
32.71
+0.00%
32.71
Diluted Average Shares
—
32.71
+0.00%
32.71
Diluted NI Availto Com Stockholders
-333.64
-36.84%
-243.81
-0.75%
-242.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Assets
594.73
+21.07%
491.24
-6.56%
525.71
Current Assets
348.92
+53.11%
227.89
-47.78%
436.43
Cash Cash Equivalents And Short Term Investments
335.98
+52.64%
220.11
-48.86%
430.41
Cash And Cash Equivalents
104.90
-18.79%
129.18
+14.54%
112.78
Cash Equivalents
84.96
+437.28%
15.81
-84.83%
104.27
Cash Financial
19.94
-82.41%
113.37
+1230.74%
8.52
Other Short Term Investments
231.07
+154.12%
90.93
-71.37%
317.63
Restricted Cash
0.40
+0.00%
0.40
0.00
Other Current Assets
12.54
+69.99%
7.38
+22.72%
6.01
Total Non Current Assets
245.82
-6.66%
263.35
+194.98%
89.28
Net PPE
233.86
-9.75%
259.13
+198.26%
86.88
Gross PPE
276.78
-5.55%
293.03
+177.04%
105.78
Accumulated Depreciation
-42.91
-26.58%
-33.90
-79.42%
-18.89
Properties
0.00
0.00
0.00
Machinery Furniture Equipment
23.85
+23.68%
19.28
+29.05%
14.94
Construction In Progress
0.62
-99.36%
96.86
+1688.37%
5.42
Other Properties
131.72
-16.78%
158.28
+135.96%
67.08
Leases
120.59
+547.87%
18.61
+1.51%
18.34
Non Current Deferred Assets
3.60
—
—
Other Non Current Assets
8.35
+98.01%
4.22
+75.86%
2.40
Total Liabilities Net Minority Interest
1,473.77
+38.62%
1,063.17
+22.62%
867.08
Current Liabilities
55.01
-2.55%
56.45
+79.55%
31.44
Payables And Accrued Expenses
44.94
-4.05%
46.84
+81.55%
25.80
Payables
0.68
-96.13%
17.58
+703.75%
2.19
Accounts Payable
0.68
-96.13%
17.58
+703.75%
2.19
Current Accrued Expenses
44.26
+51.26%
29.26
+23.92%
23.61
Current Debt And Capital Lease Obligation
10.03
+7.75%
9.31
+84.37%
5.05
Current Capital Lease Obligation
10.03
+7.75%
9.31
+84.37%
5.05
Other Current Liabilities
0.04
-88.37%
0.30
-49.07%
0.59
Total Non Current Liabilities Net Minority Interest
1,418.76
+40.93%
1,006.72
+20.47%
835.64
Long Term Debt And Capital Lease Obligation
247.29
+28.03%
193.15
+623.77%
26.69
Long Term Capital Lease Obligation
247.29
+28.03%
193.15
+623.77%
26.69
Other Non Current Liabilities
10.00
+86.99%
5.35
+632.60%
0.73
Preferred Securities Outside Stock Equity
1,161.47
+43.71%
808.22
+0.00%
808.22
Stockholders Equity
-879.03
-53.70%
-571.93
-67.54%
-341.37
Common Stock Equity
-879.03
-53.70%
-571.93
-67.54%
-341.37
Capital Stock
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
Share Issued
53.98
+0.00%
53.98
+0.00%
53.98
Ordinary Shares Number
53.98
+0.00%
53.98
+0.00%
53.98
Additional Paid In Capital
41.48
+25.64%
33.01
+67.11%
19.75
Retained Earnings
-920.51
-52.17%
-604.94
-67.51%
-361.13
Total Equity Gross Minority Interest
-879.03
-53.70%
-571.93
-67.54%
-341.37
Total Capitalization
-879.03
-53.70%
-571.93
-67.54%
-341.37
Working Capital
293.91
+71.44%
171.44
-57.67%
404.99
Invested Capital
-879.03
-53.70%
-571.93
-67.54%
-341.37
Total Debt
257.32
+27.10%
202.46
+537.97%
31.73
Capital Lease Obligations
257.32
+27.10%
202.46
+537.97%
31.73
Net Tangible Assets
-879.03
-53.70%
-571.93
-67.54%
-341.37
Tangible Book Value
-879.03
-53.70%
-571.93
-67.54%
-341.37
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Operating Cash Flow
-188.52
-39.85%
-134.80
+29.37%
-190.85
Cash Flow From Continuing Operating Activities
-188.52
-39.85%
-134.80
+29.37%
-190.85
Net Income From Continuing Operations
-324.25
-32.99%
-243.81
-0.75%
-242.00
Depreciation Amortization Depletion
24.18
-4.79%
25.39
+43.07%
17.75
Depreciation
24.18
-4.79%
25.39
+43.07%
17.75
Depreciation And Amortization
24.18
-4.79%
25.39
+43.07%
17.75
Other Non Cash Items
-5.54
+41.40%
-9.46
-168.09%
13.89
Stock Based Compensation
18.04
+45.11%
12.43
+30.31%
9.54
Asset Impairment Charge
21.23
0.00
—
Change In Working Capital
77.83
-3.49%
80.65
+708.44%
9.98
Change In Prepaid Assets
-5.16
-278.04%
-1.37
+25.36%
-1.83
Change In Payables And Accrued Expense
12.80
+57.77%
8.12
-53.17%
17.33
Change In Accrued Expense
16.62
+221.77%
5.16
-69.79%
17.09
Change In Payable
-3.81
-229.21%
2.95
+1134.73%
0.24
Change In Account Payable
-3.81
-229.21%
2.95
+1134.73%
0.24
Change In Other Current Assets
-1.26
+30.60%
-1.82
-243.53%
1.27
Change In Other Current Liabilities
71.46
-5.63%
75.72
+1214.86%
-6.79
Investing Cash Flow
-181.34
-219.82%
151.35
+10.51%
136.95
Cash Flow From Continuing Investing Activities
-181.34
-219.82%
151.35
+10.51%
136.95
Net PPE Purchase And Sale
-46.74
+44.88%
-84.80
-197.42%
-28.51
Purchase Of PPE
-46.74
+44.88%
-84.80
-197.42%
-28.51
Capital Expenditure
-46.74
+44.88%
-84.80
-197.42%
-28.51
Net Investment Purchase And Sale
-134.60
-157.00%
236.15
+42.72%
165.46
Purchase Of Investment
-444.10
-23.24%
-360.35
+55.22%
-804.74
Sale Of Investment
309.50
-48.11%
596.50
-38.52%
970.20
Financing Cash Flow
352.05
+144184.02%
0.24
-99.77%
105.81
Cash Flow From Continuing Financing Activities
352.05
+144184.02%
0.24
-99.77%
105.81
Net Common Stock Issuance
1.90
+678.69%
0.24
-39.30%
0.40
Changes In Cash
-17.81
-206.02%
16.80
-67.65%
51.91
Beginning Cash Position
130.88
+14.72%
114.08
+83.50%
62.17
End Cash Position
113.07
-13.61%
130.88
+14.72%
114.08
Free Cash Flow
-235.26
-7.13%
-219.60
-0.11%
-219.36
Interest Paid Supplemental Data
0.89
+2767.74%
0.03
-20.51%
0.04
Common Stock Issuance
1.90
+678.69%
0.24
-39.30%
0.40
Issuance Of Capital Stock
352.05
+144184.02%
0.24
-99.77%
105.81
Net Preferred Stock Issuance
350.15
0.00
-100.00%
105.41
Preferred Stock Issuance
350.15
0.00
-100.00%
105.41
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category